Video

Psychedelic-Assisted Therapy: A clinician’s perspective

Date

20 July 2023

Organised by

RANZCP
Psychedelics

In Australia, the Therapeutic Goods Administration (TGA) permits the use of MDMA and psilocybin for the treatment of certain mental health conditions. From 1 July 2023, authorised psychiatrists can prescribe MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression.

Join Professor Colleen Loo, Dr Nigel Strauss and Dr Justin Dwyer as they talk about their clinical experience with psychedelic-assisted therapy followed by a Q&A discussion with RANZCP President, Dr Elizabeth Moore.

More about the RANZCP guidelines for psychedelic-assisted therapy

Presenters

Graphic-ProfileArc

Professor Colleen Loo

Colleen Loo is a psychiatrist, Australian National Health and Medical Research Council Leadership Fellow and Professor of Psychiatry at the University of New South Wales in Sydney and the Black Dog Institute, Sydney; Australia. She is an internationally recognised clinical expert and researcher in the fields of electroconvulsive therapy, Transcranial Magnetic Stimulation, transcranial Direct Current Stimulation and ketamine, and led the first Australian RCTs of these interventions in depression. She has published over 300 peer reviewed papers and has received competitive grant funding from the Australian NHMRC, MRFF and major overseas grant funding agencies.
 
Prof Loo is active in ECT, Neurostimulation and novel treatments research, practice and policy, providing advice to Australian government health departments, the Royal Australian and New Zealand College of Psychiatrists, and several  international guidelines. She was President of the International Society for ECT and Neurostimulation (ISEN) 2018-2020. She has served on the Editorial Boards of the two leading international brain stimulation journals: Journal of ECT, Brain Stimulation. She directs professional training courses in ECT, TMS, tDCS and ketamine. 

Colleen Loo is a psychiatrist, Australian National Health and Medical Research Council Leadership Fellow and Professor of Psychiatry at the University of New South Wales in Sydney and the Black Dog Institute, Sydney; Australia. She is an internationally recognised clinical expert and researcher in the fields of electroconvulsive therapy, Transcranial Magnetic Stimulation, transcranial Direct Current Stimulation and ketamine, and led the first Australian RCTs of these interventions in depression. She has published over 300 peer reviewed papers and has received competitive grant funding from the Australian NHMRC, MRFF and major overseas grant funding agencies.
 
Prof Loo is active in ECT, Neurostimulation and novel treatments research, practice and policy, providing advice to Australian government health departments, the Royal Australian and New Zealand College of Psychiatrists, and several  international guidelines. She was President of the International Society for ECT and Neurostimulation (ISEN) 2018-2020. She has served on the Editorial Boards of the two leading international brain stimulation journals: Journal of ECT, Brain Stimulation. She directs professional training courses in ECT, TMS, tDCS and ketamine. 

Graphic-ProfileArc

Dr Nigel Strauss

Nigel Strauss is a psychiatrist in private practice and senior consultant with St Vincent’s Hospital Melbourne, an investigator on several psychedelic clinical trials, and is on the scientific advisory board of the European Mind Foundation. He has made his own philanthropic donation to Monash University for a trial of MDMA assisted psychotherapy for PTSD. He has a long interest in psychedelic assisted psychotherapy and has been a co-author of several published papers on psychedelic therapy.

Nigel Strauss is a psychiatrist in private practice and senior consultant with St Vincent’s Hospital Melbourne, an investigator on several psychedelic clinical trials, and is on the scientific advisory board of the European Mind Foundation. He has made his own philanthropic donation to Monash University for a trial of MDMA assisted psychotherapy for PTSD. He has a long interest in psychedelic assisted psychotherapy and has been a co-author of several published papers on psychedelic therapy.

Graphic-ProfileArc

Dr Justin Dwyer

Dr. Justin Dwyer is a psychiatrist and head of unit for Psychosocial Cancer Care at St Vincent’s. Hospital Melbourne. He is Principal Investigator and member of lead therapy dyad (with Dr Margaret Ross) in the psychedelic-assisted psychotherapy trial at St Vincent’s, Melbourne. Along with Dr Ross, he has trained therapists across 3 clinical trials nationally across a range of mental health conditions and works in other trials investigating novel psychedelic compounds. He has strong views on the central importance of highly skilled and appropriately credentialed psychotherapy within the PAT paradigm. 

He has specialised in the provision of care at the intersection of physical and mental health and is particularly focused on providing psychological care to people dealing with profoundly troubling circumstances, such as serious illness and dying. He has published on various topics including on suicide in the medically ill and in Covid-19 patients, art therapy in palliative care, and the experience of music used with psychedelic therapy. 

Dr. Justin Dwyer is a psychiatrist and head of unit for Psychosocial Cancer Care at St Vincent’s. Hospital Melbourne. He is Principal Investigator and member of lead therapy dyad (with Dr Margaret Ross) in the psychedelic-assisted psychotherapy trial at St Vincent’s, Melbourne. Along with Dr Ross, he has trained therapists across 3 clinical trials nationally across a range of mental health conditions and works in other trials investigating novel psychedelic compounds. He has strong views on the central importance of highly skilled and appropriately credentialed psychotherapy within the PAT paradigm. 

He has specialised in the provision of care at the intersection of physical and mental health and is particularly focused on providing psychological care to people dealing with profoundly troubling circumstances, such as serious illness and dying. He has published on various topics including on suicide in the medically ill and in Covid-19 patients, art therapy in palliative care, and the experience of music used with psychedelic therapy. 

Graphic-ProfileArc

Dr Elizabeth Moore

President (2023–2025)

Dr Elizabeth Moore was born in Malaya, educated in England and Australia, completing her undergraduate medical degree at the University of Adelaide before attaining Fellowship of the RANZCP in 1990.

Dr Moore has worked in both public and private hospital and community settings, holding clinical and administrative positions in psychiatry in South Australia, New South Wales, Victoria and Western Australia and is the inaugural ACT Coordinator-General of the Office of Mental Health and Wellbeing.

Dr Moore assumed the role of President of the RANZCP in May 2023 for a two-year term.

Dr Elizabeth Moore was born in Malaya, educated in England and Australia, completing her undergraduate medical degree at the University of Adelaide before attaining Fellowship of the RANZCP in 1990.

Dr Moore has worked in both public and private hospital and community settings, holding clinical and administrative positions in psychiatry in South Australia, New South Wales, Victoria and Western Australia and is the inaugural ACT Coordinator-General of the Office of Mental Health and Wellbeing.

Dr Moore assumed the role of President of the RANZCP in May 2023 for a two-year term.

Frequently asked questions

How do I get my certificate of attendance?

Certificates of attendance are provided for live attendance. If you attended this webinar live and are yet to receive your certificate, please contact events@ranzcp.org.

Disclaimer

This session is a Member benefit of the RANZCP and for educational purposes only. The information may represent views of the author and not necessarily the views of the College. Information is subject to change and the College does not warrant that the information is current at the time of viewing and accepts no liability for any loss or damage suffered by you or a patient directly or indirectly as a result of relying on information provided and should not be a substitute for individual clinical judgement. By accessing e-learning sessions you also agree to the RANZCP Website Terms of Use Agreement.